Hum Mutat:POLD1变异导致聚合酶活性减少从而引起无症状特征听力损失

2020-01-27 AlexYang MedSci原创

DNA聚合酶δ的催化亚单元是由POLD1编码,负责合成DNA的滞后链。据报道,聚合酶活性和外切酶活性结构域的单个不同的POLD1变异能够引起综合症性耳聋,并且只是多系统代谢紊乱或易患癌症的一部分。然而,POLD1不同基因型组合的表型在人类中尚未阐释。最近,有研究人员在一个多重家族分离常染色体隐性遗传非综合征性感音神经性耳聋(NS-SNHL)家族中,发现了其中5名成员具有新的复合杂合子POLD1变异

DNA聚合酶δ的催化亚单元是由POLD1编码,负责合成DNA的滞后链。据报道,聚合酶活性和外切酶活性结构域的单个不同的POLD1变异能够引起综合症性耳聋,并且只是多系统代谢紊乱或易患癌症的一部分。然而,POLD1不同基因型组合的表型在人类中尚未阐释。

最近,有研究人员在一个多重家族分离常染色体隐性遗传非综合征性感音神经性耳聋(NS-SNHL)家族中,发现了其中5名成员具有新的复合杂合子POLD1变异(p.Gly1100Arg和一个假定的无义变异 p.Ser197Hisfs*54)。研究人员发现,重组的p.Gly1100Arg聚合酶δ的聚合酶活性减少30%-40%,但是表现出了正常的外切酶活性。携带2个POLD1变异等位基因的受影响受试者细胞提取物中聚合酶活性大约是正常对照聚合酶活性的33%。

最后,研究人员指出,聚合酶δ活性的显著减少而非完全缺失,且具有正常的外切酶活性能够导致NS-SNHL。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1955989, encodeId=f01319559895c, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Jul 26 11:33:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306475, encodeId=12c513064e5ea, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Jan 29 04:33:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342644, encodeId=417b1342644a9, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Jan 29 04:33:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485055, encodeId=1373148505571, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Jan 29 04:33:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
    2020-07-26 晓辰
  2. [GetPortalCommentsPageByObjectIdResponse(id=1955989, encodeId=f01319559895c, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Jul 26 11:33:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306475, encodeId=12c513064e5ea, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Jan 29 04:33:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342644, encodeId=417b1342644a9, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Jan 29 04:33:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485055, encodeId=1373148505571, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Jan 29 04:33:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
    2020-01-29 ysjykql
  3. [GetPortalCommentsPageByObjectIdResponse(id=1955989, encodeId=f01319559895c, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Jul 26 11:33:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306475, encodeId=12c513064e5ea, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Jan 29 04:33:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342644, encodeId=417b1342644a9, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Jan 29 04:33:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485055, encodeId=1373148505571, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Jan 29 04:33:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1955989, encodeId=f01319559895c, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Jul 26 11:33:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306475, encodeId=12c513064e5ea, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Jan 29 04:33:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342644, encodeId=417b1342644a9, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Jan 29 04:33:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485055, encodeId=1373148505571, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Jan 29 04:33:00 CST 2020, time=2020-01-29, status=1, ipAttribution=)]

相关资讯

Laryngoscope:总体心血管健康与听力损失的关系研究

最近,有研究人员在一个非裔美国人心血管研究群体中评估了总体心血管健康评分与听力之间的关系。研究人员评估了1314名参与者的LS7评分指标(总心血管评分工具,Life's Simple 7(LS7))与听力之间的关系。研究人员收集了标准听力测定数据,并将听力损失定义为在500、1000、2000和4000Hz时大于25dBHL(PTA4)。研究人员同样搜集了报道的耳鸣和头晕测量数据。研究发现,在γ回

盘点:耳聋研究

听力损失(hearing loss)又称聋度(deafness)或听力级(hearing level)。是人耳在某一频率的听阈比正常听阈高出的分贝数。由于年龄关系产生的听力损失称为老年性耳聋;由于社会环境噪声(年龄、职业性噪声和疾病等影响除外)产生的听力损失称为社会性耳聋;职业性噪声导致的听力损失称为噪声性耳聋。梅斯医学小编整理了近期听力损失的研究进展,与大家一起分享学习!【1】Asia Pa

Am J Audiol:突发性感觉神经性听力损失的复发研究

突发性感觉神经性听力损失(SSNHL)的长期治疗结果很少有研究。其复发比例是异质性的,并且复发的预后并不清楚。最近,有研究人员评估了SSNHL的复发率情况,并分析了临床和听力特征之间的相关性。研究人员对73名自发性SSNHL患者进行了评估。其中70名患者(95.8%)进行了至少2年的跟踪调查,而50(68.4%)名患者跟踪调查时间为5年。研究发现,2年和5年的复发率分别为5.6%和10.34%。首

盘点:听力损失治疗研究

【1】Am J Otolaryngol:听觉剥夺成年人中的耳蜗移植分析 在耳鼻喉科领域,听觉剥夺经常被认为是一种耳蜗移植(CI)后良好听力结果的一个负面预后因素,尽管越来越多的文献表明上述情况未必完全属实。最近,有研究人员评估了CI在听力剥夺患者中的结果情况,并与非剥夺患者的结果进行了比较,之后还评估了剥夺时间怎样对CI结果产生影响,以及双边剥夺怎样能够影响结果,并与单边剥夺进行

JAMA Otolaryngol Head Neck Surg:视网膜微血管征和年龄相关的听力损失相关性研究

年龄相关的听力损失是高度可预防和治疗的,理解该疾病的病因对疾病的预防可能有帮助。最近,有研究人员调查了是否微血管征与年龄相关的听力损失相关。研究包括了1458名个体(平均年龄(SD),76.1(5.0)岁(年龄范围67-90岁);825名女性(56.6%);285名黑人(19.5%))。在具有或者不具有视网膜疾病的个体中,每dB听力水平PTA的差异为2.21(95%CI, -0.22到4.63),

Pediatr Infect Dis J:先天性巨细胞病毒感染儿童中中耳积液研究

感觉神经听力损失(SNHL)在患有先天性巨细胞病毒感染(CMV)的儿童中已经有了详细的阐述,但是关于该群体中耳积液(MEE)的情况数据仍旧有限。最近,有研究人员评估了MEE和与MEE相关的暂时性听力变化程度与先天性CMV感染之间的相关性情况。研究是一个纵向的研究,包括了先天性CMV感染并接受了听力和鼓室测试的儿童,跟踪调查的时间直至最大6岁。研究发现,72名有症状的患者中44名(61%)因MEE就